13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0002050709
Total reported value
$322.2M
$322.2M
33 檔
34.5%
As reported in its official Q4 2025 Form 13F filing, Squadron Capital Management LLC's tracked investment portfolio stood at $322.2M with 33 total positions.
During Q4 2025, Squadron Capital Management LLC's portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | RLMD | Relmada Therapeutics Inc | Stock-Other | 13.71% | -5.83% | — | |
| 2 | COGT | Cogent Biosciences Inc | Stock-Other | 11.74% | -0.72% | — | |
| 3 | MAZE | Maze Therapeutics Inc | Stock-Other | 8.60% | +0.28% | — | |
| 4 | ABVX | Abivax Sa-adr | Stock-Other | 8.29% | -5.30% | EXIT | |
| 5 | 4XC1 | Kalvista Pharmaceuticals Inc | Stock-Other | 4.79% | -9.59% | EXIT | |
| 6 | PALI | Palisade Bio Inc | Stock-Other | 4.48% | +0.03% | — | |
| 7 | EWTX | Edgewise Therapeutics Inc | Stock-Other | 3.68% | -0.38% | — | |
| 8 | IKT | Inhibikase Therapeutics Inc | Stock-Other | 3.67% | -0.26% | — | |
| 9 | KOD | Kodiak Sciences Inc | Stock-Other | 3.46% | +0.74% | — | |
| 10 | 430 | Terns Pharmaceuticals Inc | Stock-Other | 3.25% | — | — | |
| 11 | AVBP | Arrivent Biopharma Inc | Stock-Other | 2.88% | +1.04% | — | |
| 12 | TARS | Tarsus Pharmaceuticals Inc | Stock-Other | 2.78% | — | — | |
| 13 | UPB | Upstream Bio Inc | Stock-Other | 2.65% | — | — | |
| 14 | SPRB | Spruce Biosciences Inc | Stock-Other | 2.58% | -0.29% | EXIT | |
| 15 | XENE | Xenon Pharmaceuticals Inc | Stock-Other | 2.00% | — | — | |
| 16 | DBVT | Dbv Technologies Sa-spon Adr | Stock-Other | 1.95% | — | — | |
| 17 | HELP | Cybin Inc | Stock-Other | 1.82% | — | — | |
| 18 | LPCN | Lipocine Inc | Stock-Other | 1.80% | -0.68% | — | |
| 19 | BLTE | Belite Bio Inc - Adr | Stock-Other | 1.76% | — | — | |
| 20 | GHRS | GH Research PLC | Stock-Other | 1.70% | -1.67% | EXIT | |
| 21 | EPRX | Eupraxia Pharmaceuticals Inc | Stock-Other | 1.60% | -1.80% | EXIT | |
| 22 | VTYXUSD | Ventyx Biosciences Inc | Stock-Other | 1.57% | — | — | |
| 23 | NXTC | Nextcure Inc | Stock-Other | 1.42% | -1.01% | — | |
| 24 | VERA | Vera Therapeutics Inc | Stock-Other | 1.29% | — | — | |
| 25 | WVE | Wave Life Sciences Ltd. | Stock-Other | 1.26% | — | — | |
| 26 | KTTA | Pasithea Therapeutics CORP | Stock-Other | 1.15% | -0.41% | — | |
| 27 | CMPS | Compass Pathways PLC | Stock-Other | 1.14% | +2.66% | NEW | |
| 28 | AVTX | Avalo Therapeutics Inc | Stock-Other | 1.00% | — | — | |
| 29 | IVA | Inventiva SA - Adr | Stock-Other | 0.59% | +1.77% | — | |
| 30 | ZBIO | Zenas Biopharma Inc | Stock-Other | 0.55% | — | — | |
| 31 | TRAW | Traws Pharma Inc | Stock-Other | 0.34% | -0.34% | EXIT | |
| 32 | NTLA | Intellia Therapeutics Inc | Stock-Other | 0.31% | — | — | |
| 33 | CLYM | Climb Bio Inc | Stock-Other | 0.17% | — | — |
According to official SEC Form 13F filings, Squadron Capital Management LLC reported a total U.S. public equity portfolio value of $322.2M across 33 disclosed positions in Q4 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including RLMD, COGT, MAZE) accounted for 34.5% of total reported equity market value during Q4 2025.
During Q4 2025, Squadron Capital Management LLC's top holdings by market value included RLMD (13.7%)、COGT (11.7%)、MAZE (8.6%). The largest single position, RLMD, represented 13.7% of total portfolio value.
In Q4 2025, Squadron Capital Management LLC made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.